Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. (Q37021822)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

review article

1 reference

title

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

0 references

1 reference

1 reference

1 reference

George Papatheodoridis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Spilios Manolakopoulos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Geoffrey Dusheiko

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Athanasios J Archimandritis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

28 November 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json

Lancet Infectious Diseases

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

167-178

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B virus infection

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Hepatitis B: an important public health issue

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Global programme for control of hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Review article: current management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Emerging treatments in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

1 reference

7 January 2021

Natural history and prognosis of hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

The natural history of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Hepatitis B virus genotypes in the United States: results of a nationwide study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Diagnosis and management of pre-core mutant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

The role of pre-core hepatitis B virus mutants on the long-term outcome of chronic hepatitis B virus hepatitis. A longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Natural history and prognostic factors for chronic hepatitis type B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Survival in chronic hepatitis B. An analysis of 379 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Hepatitis B virus. The major etiology of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

The natural history of asymptomatic hepatitis B surface antigen carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Long-term remission of chronic hepatitis B after alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Chronic hepatitis B: update of recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Prompt relapse of viremia after lamivudine discontinuation in e-minus chronic hepatitis B patients completely responders during 5 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

HBV drug resistance: mechanisms, detection and interpretation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Mutation rate of the hepadnavirus genome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Clinical relevance of hepatitis B viral mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Histological outcome during long-term lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Hepatitis B virus mutations associated with antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Virologic response and resistance to adefovir in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Tenofovir disoproxil fumarate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Resistance to lamivudine therapy: is there more than meets the eye?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Cellular and virological mechanisms of HBV drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Variant of hepatitis B virus with primary resistance to adefovir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Antiviral drug resistance: clinical consequences and molecular aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Drugs in development for hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970264-5

7 January 2021

10.1016/S1473-3099(07)70264-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18053766%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference